Scottish Medicines Consortium rejects Novartis’ CAR T therapy Kymriah

pharmafile | March 12, 2019 | News story | Manufacturing and Production |  Kymriah, NICE, Novartis, SMC, Scotland, UK 

Scotland’s cost effectiveness body has refused to fund Novartis’ CAR T therapy Kymriah for adult patients with lymphoma.

The Scottish Medicines Consortium (SMC) said that it could not accept Kymriah as a treatment for adult patients with diffuse B cell lymphoma who have relapsed or not responded after two previous lines of treatment.

The decision follows a similar one from England and Wales cost regulator, NICE, last year. The government body rejected Kymriah as a treatment for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Advertisement

The body concluded that Novartis’ cancer immunotherapy was not cost effective for routine funding on the NHS in England and Wales or use within the Cancer Drugs Fund (CDF).

Scottish authorities however made their decision “because of uncertainties in the company’s evidence around its long term benefits.”

Neverthless both NICE and the SMC have approved funding for Kymriah in its other licensed indication for lymphoblastic leukaemia in children and young adults who have not responded to previous treatment or in whom the condition has relapsed.

Louis Goss

Related Content

Major funding opportunity opens for early cancer diagnostics

Up to £25.4m in funding is available for collaborative projects developing technologies to improve the …

NICE recommends allergy immunotherapy tablets for younger children

NICE has recommended two sublingual immunotherapy tablets for children with moderate to severe allergic rhinitis …

NICE backs atogepant for acute migraine treatment

NICE has issued Final Draft Guidance recommending AbbVie’s AQUIPTA (atogepant) as an option for the …

The Gateway to Local Adoption Series

Latest content